TLDR Topical cyclosporin A may help treat psoriasis but has absorption and side effect challenges.
The document discussed the use of topical cyclosporin A in treating psoriasis and other dermatological diseases. It explored both theoretical and practical aspects of this treatment approach. The study highlighted cyclosporin A's potential effectiveness due to its immunosuppressive properties, which could help in managing inflammatory skin conditions. However, the document also noted challenges such as the drug's absorption through the skin and potential side effects. The research provided insights into the benefits and limitations of using cyclosporin A topically, contributing to the understanding of its role in dermatological therapy at the time.
20 citations,
March 1990 in “Archives of Dermatology” Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
16 citations,
July 1989 in “British journal of dermatology/British journal of dermatology, Supplement” Topical cyclosporin A doesn't work for alopecia totalis because it doesn't penetrate the skin well.
22 citations,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
111 citations,
March 2012 in “Expert Opinion on Drug Delivery” Liposomes could improve how skin care products work but are costly and not very stable.
21 citations,
January 2022 in “Pharmaceutics” Colchicine might help treat different skin diseases, but more research is needed to confirm its effectiveness and safe dosage.
36 citations,
December 2015 in “Drugs” New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
60 citations,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
